Furthermore, no matter when treatment is initiated, many individuals with SMA will continue to experience reduced levels of functioning, significant weakness and decreased quality of life while on SMN upregulator therapy [13,19,24,25,26,27]. Here, SMN2 is linked to proximal spinal muscular atrophy.